ANALYSIS OF CONTROLLED TRIAL OF CHLORAMBUCIL VS. PLACEBO

苯丁酸氮芥对​​照试验分析

基本信息

  • 批准号:
    3267657
  • 负责人:
  • 金额:
    $ 1.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1983
  • 资助国家:
    美国
  • 起止时间:
    1983-11-15 至 1986-03-31
  • 项目状态:
    已结题

项目摘要

Scleroderma (PSS) is not a benign disease and is associated with high mortality and morbidity. Until very recently there has been remarkably little progress in the treatment of this disease. A number of drugs have been studied but none have been shown to be efficacious. Over the last 9 years we have been involved in a double-blind, parallel, study of chlorambucil versus placebo in which each patient is on the study drug for 3 years. At the present time we have enrolled 70 patients. The quality of the data generated from this study has resulted in the publication of 18 descriptive articles and the preparation of several more. These publications attest to our ability to maintain the quality of the data. Further, we have been able to maintain the double-blind nature of the study. We propose, in this application, to analyze the results of this study. Using statistical techniques such as chi-square analysis, t statistics, ANOVA, covariance analysis, multi-variate techniques and power analysis, we will examine outcome measures such as mortality, failure or drop out rates, differences in functional outcome and changes in individual and combined measures of visceral function over time. At the end of the 2 years required for this analysis we will: 1) have evaluated the efficacy of Chlorambucil in stablizing and/or improving PSS; 2) have evaluated the reliability and sensitivity of a set of measurements which objectively measure changes in PSS activity; 3) hope to have developed prognostic indicies to predict which patients could most benefit from this drug therapy.
硬皮病(PSS)不是一种良性疾病,与高

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel Eric Furst其他文献

Daniel Eric Furst的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel Eric Furst', 18)}}的其他基金

Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
弥漫性系统性硬化症患者的临时综合缓解指数
  • 批准号:
    7478569
  • 财政年份:
    2007
  • 资助金额:
    $ 1.77万
  • 项目类别:
Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
弥漫性系统性硬化症患者的临时综合缓解指数
  • 批准号:
    7678566
  • 财政年份:
    2007
  • 资助金额:
    $ 1.77万
  • 项目类别:
Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
弥漫性系统性硬化症患者的临时综合缓解指数
  • 批准号:
    7485930
  • 财政年份:
    2007
  • 资助金额:
    $ 1.77万
  • 项目类别:
Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
弥漫性系统性硬化症患者的临时综合缓解指数
  • 批准号:
    7282901
  • 财政年份:
    2007
  • 资助金额:
    $ 1.77万
  • 项目类别:
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
口服环磷酰胺与口服安慰剂治疗 SSC 肺泡炎
  • 批准号:
    6390015
  • 财政年份:
    1999
  • 资助金额:
    $ 1.77万
  • 项目类别:
ANALYSIS OF CONTROLLED TRIAL OF CHLORAMBUCIL VS. PLACEBO
苯丁酸氮芥对​​照试验分析
  • 批准号:
    3267658
  • 财政年份:
    1983
  • 资助金额:
    $ 1.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了